Biohaven Pharmaceutical Holding Co Ltd. Contracts & Agreements

Agreement and Plan of Merger, dated as of May 9, 2022, by and among Pfizer Inc., Bulldog (BVI) Ltd. and Biohaven Pharmaceutical Holding Company Ltd (Filed With SEC on May 11, 2022)

Separation and Distribution Agreement, dated as of May 9, 2022, by and between Biohaven Pharmaceutical Holding Company Ltd. and Biohaven Research Ltd (Filed With SEC on May 11, 2022)

Membership Interest Purchase Agreement, dated as of February 24, 2022, by and among Biohaven Therapeutics LTD., Knopp Biosciences LLC, Channel Biosciences, LLC and Biohaven... (Filed With SEC on May 10, 2022)

Amendment No. 1 to Employment Agreement, dated December 14, 2021, by and between Biohaven Pharmaceuticals, Inc. and James Engelhart (Filed With SEC on February 25, 2022)

Amendment No. 4 to Financing Agreement, dated as of December 28, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc., the guarantors... (Filed With SEC on February 25, 2022)

2022 Deferral Election (Filed With SEC on December 30, 2021)

Consulting Agreement, dated December 5, 2021, between the Company and Declan Doogan (Filed With SEC on December 9, 2021)

Employment Agreement, dated December 8, 2021, between the Company and Matthew Buten (Filed With SEC on December 9, 2021)

Agreement and Plan of Merger, dated November 9, 2021, by and among Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Atlas Merger Sub and BioShin Ltd (Filed With SEC on November 12, 2021)

Collaboration Agreement, dated November 9, 2021, by and among Pfizer Ireland Pharmaceuticals, Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and... (Filed With SEC on November 12, 2021)

Sublicense Agreement, dated November 9, 2021, by and among Pfizer Ireland Pharmaceuticals, Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and... (Filed With SEC on November 12, 2021)

Subscription Agreement, dated November 9, 2021, by and between Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd (Filed With SEC on November 12, 2021)

Amendment No. 3 and Limited Consent to Financing Agreement, dated November 9, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc.,... (Filed With SEC on November 12, 2021)

Underwriting Agreement, dated as of March 15, 2021, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on March 17, 2021)

Agreement and Plan of Merger, dated as of January 1, 2021, by and between Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Kleo Acquisition, Inc., Kleo... (Filed With SEC on January 8, 2021)

Equity Distribution Agreement, dated as of December 23, 2020, by and between Biohaven Pharmaceutical Holding Company Ltd. and Goldman Sachs & Co. LLC, Piper Sandler & Co., SVB... (Filed With SEC on December 23, 2020)

Funding Agreement by and (Filed With SEC on November 9, 2020)

Amendment No. 1 (Filed With SEC on November 9, 2020)

Series B Preferred Share Purchase Agreement by and (Filed With SEC on November 9, 2020)

Description of Biohaven's Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)

Employment Agreement dated March 30, 2019 by and between Biohaven Pharmaceuticals, Inc. and William Jones, Jr (Filed With SEC on February 26, 2020)

Employment Agreement dated February 1, 2014 by and between Biohaven Pharmaceuticals, Inc. and Kimberly A. Gentile (Filed With SEC on February 26, 2020)

Offer Letter dated April 5, 2017 by and between Biohaven Pharmaceuticals, Inc. and Elyse Stock (Filed With SEC on February 26, 2020)

Zydis Commercial Supply Agreement, dated as of June 29, 2018, by and between Biohaven Pharmaceuticals, Inc. and Catalent U.K. Swindon Zydis Limited (Filed With SEC on February 26, 2020)

Underwriting Agreement, dated as of January 28, 2020, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on January 30, 2020)

Underwriting Agreement, dated as of June 18, 2019 by and among the Company and Goldman Sachs & Co. LLC and Piper Jaffray & Co., as Representatives of the several Underwriters... (Filed With SEC on June 21, 2019)

Series A Preferred Share Purchase Agreement, dated as of March 18, 2019 (Filed With SEC on May 8, 2019)

PRV Transfer Agreement (Filed With SEC on March 18, 2019)

Form of Underwriting Agreement (Filed With SEC on December 10, 2018)

Amendment to License Agreement, dated September 4, 2018, by and between Biohaven Therapeutics Ltd. and AstraZeneca AB (Filed With SEC on November 14, 2018)

Amendment to License Agreement, dated March 9, 2018, by and between Biohaven Pharmaceutical Holding Company Ltd. and Bristol-Myers Squibb Company (Filed With SEC on August 14, 2018)

Funding Agreement, dated June 18, 2018, by and between Biohaven Pharmaceutical Holding Company Ltd. and RPI Finance Trust (Filed With SEC on June 25, 2018)

Common Stock Purchase Agreement, dated June 18, 2018, by and between Biohaven Pharmaceutical Holding Company Ltd. and RPI Finance Trust (Filed With SEC on June 25, 2018)

Securities Purchase Agreement, dated March 9, 2018 (Filed With SEC on March 12, 2018)

Registration Rights Agreement, dated March 9, 2018 (Filed With SEC on March 12, 2018)

First Subscription Agreement between Kleo Pharmaceuticals, Inc. and the Registrant, dated as of October 5, 2017 (Filed With SEC on October 12, 2017)

Second Subscription Agreement between Kleo Pharmaceuticals, Inc. and the Registrant, dated as of October 5, 2017 (Filed With SEC on October 12, 2017)

SECURITIES PURCHASE AGREEMENT BETWEEN KLEO PHARMACEUTICALS, INC. AND BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LIMITED. Dated as of August 29, 2016 (Filed With SEC on June 14, 2017)

INDEMNIFICATION AGREEMENT (Filed With SEC on May 1, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on May 1, 2017)

Shares BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. COMMON SHARES, WITHOUT PAR VALUE UNDERWRITING AGREEMENT (Filed With SEC on April 24, 2017)

ALS BIOPHARMA AGREEMENT (Filed With SEC on April 24, 2017)

Table of Contents (Filed With SEC on April 24, 2017)

ZYDIS DEVELOPMENT AND LICENSE AGREEMENT (Riluzole) (Filed With SEC on April 24, 2017)

THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125 (Filed With SEC on April 24, 2017)

EXCLUSIVE LICENSE AGREEMENT between Biohaven Pharmaceutical Holding Co. Ltd and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (Filed With SEC on April 24, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 6, 2017 APPROVED BY THE SHAREHOLDERS: , 2017 IPO DATE: , 2017 (Filed With SEC on April 24, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. SHARE OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) (Filed With SEC on April 24, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. RESTRICTED SHARE UNIT GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) (Filed With SEC on April 24, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. 2017 EMPLOYEE SHARE PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 6, 2017 APPROVED BY THE SHAREHOLDERS: [ ] (Filed With SEC on April 24, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. INVESTORS RIGHTS AGREEMENT October 28, 2016 (Filed With SEC on April 7, 2017)

TERM NOTE (Filed With SEC on April 7, 2017)

WARRANT No. 3 (Filed With SEC on April 7, 2017)

WARRANT No. 4 (Filed With SEC on April 7, 2017)

WARRANT No. 1 (Filed With SEC on April 7, 2017)

LICENSE AGREEMENT between BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. and BRISTOL-MYERS SQUIBB COMPANY CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE... (Filed With SEC on April 7, 2017)

ALS BIOPHARMA AGREEMENT (Filed With SEC on April 7, 2017)

LICENCE AGREEMENT (Filed With SEC on April 7, 2017)

Table of Contents (Filed With SEC on April 7, 2017)

ZYDIS DEVELOPMENT AND LICENSE AGREEMENT (Riluzole) (Filed With SEC on April 7, 2017)

THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125 (Filed With SEC on April 7, 2017)

EXCLUSIVE LICENSE AGREEMENT between Biohaven Pharmaceutical Holding Co. Ltd and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (Filed With SEC on April 7, 2017)

CREDIT AGREEMENT (Filed With SEC on April 7, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. 2014 EQUITY INCENTIVE PLAN Section 1 Title (Filed With SEC on April 7, 2017)

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. 2014 EQUITY INCENTIVE PLAN Share Option Agreement (Filed With SEC on April 7, 2017)

Category

Industry

Companies

Contracts

Biohaven Pharmaceutical Holding Co Ltd. Contracts & Agreements